Phase 1 trial of QXL138AM: A Targeted Therapy for Prostate Cancer and Other CD138-Expressing Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial of INV-9956: A Promising CYP11A1 Inhibitor Targeting Drug-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Enrolling: Novel Copper-61 Radiotracer Shows Promise in Prostate Cancer Precision Imaging
/0 Comments/in Clinical Trial, Localized, Metastatic, Non-Metastatic, Phase 1, Phase 1/by MaxPhase I Trial for Novel Cancer Drug: VVD-130850
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxInvikafusp Alfa: New Hope for Advanced, Anti-PD-1 Resistant Cancers Phase 1 and 2 Trial
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxSequencing Radium-223 and Lutetium-177 PSMA Therapy in mCRPC Management: Insights from the RaLu Trial
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxB7-H4-Targeting Antibody-Drug Conjugate, LNCB74, Gets Green Light for Clinical Trials for Solid Tumors
/0 Comments/in Clinical Trial, Phase 1/by MaxNew Drug Receives FDA Clearance to Begin Clinical Trials
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPromising Results for B7-H3 Antibody-Drug Conjugate in Advanced Solid Tumors (including metastatic castration resistant prostate cancer)
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxTags
abiraterone acetate ADC ADT androgen deprivation therapy antibody-drug conjugate apalutamide ATM bispecific antibody cancer cancer immunotherapy cancer treatment CAR-T castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC neuroendocrine prostate cancer oncology PARP inhibitor PEACE-1 personalized medicine prostate cancer PSA response PSMA radioligand therapy real-world data small molecule survival outcomes T-cell therapy targeted drug delivery theranostics tumor microenvironment
Latest Posts
- PARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair January 18, 2025
- Update on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025 January 17, 2025
- UMass Scientists Develop Novel Bacteria-Based Cancer Therapy January 16, 2025
- Harnessing PROTAC Technology: A Novel Approach to Targeting ERG in Prostate Cancer January 15, 2025